Literature DB >> 10406499

Alterations in water and solute transport with time on peritoneal dialysis.

O Heimbürger1, T Wang, B Lindholm.   

Abstract

Peritoneal ultrafiltration capacity and small-solute transport characteristics seem to be relatively stable in most patients treated with PD for up to 3 years. However, in patients treated with PD for 4 years or more, there is a tendency towards increasing diffusive transport for small solutes as well as a tendency towards decreasing net UF, whereas the peritoneal protein clearances seem to be reduced or stable. Loss of UFC is a well-known complication during long-term PD treatment, and the risk for loss of UFC may be as high as 50% after 6 years on PD. Several different mechanisms of UFC loss have been reported. In particular, the most common mechanism for loss of UFC is increased diffusive transport resulting in rapid glucose absorption and thus rapid loss of the osmotic driving force. Also reported as causes of UFC loss have been: reduced efficiency of the osmotic agent (perhaps owing to decreased transcellular water transport); loss of peritoneal surface area with slow solute transport owing to fibrosis and the formation of adhesions (during the late stage of sclerosing peritonitis); and increased peritoneal fluid absorption. In individual patients, a combination of several mechanisms may be involved in the apparent UFC failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406499

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  12 in total

1.  The Mutual Relationship Between Peritonitis and Peritoneal Transport.

Authors:  Sadie van Esch; Anouk T N van Diepen; Dirk G Struijk; Raymond T Krediet
Journal:  Perit Dial Int       Date:  2014-11-13       Impact factor: 1.756

2.  Alterations of intercellular junctions in peritoneal mesothelial cells from patients undergoing dialysis: effect of retinoic Acid.

Authors:  Carmen Retana; Elsa Sanchez; Alejandro Perez-Lopez; Armando Cruz; Jesus Lagunas; Carmen Cruz; Socorro Vital; Jose L Reyes
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 3.  Can peritoneal dialysis be used as a long term therapy for end stage renal disease?

Authors:  Michele Giannattasio; Michele Buemi; Flavia Caputo; Giusto Viglino; Enrico Verrina
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 4.  Peritoneal changes in patients on long-term peritoneal dialysis.

Authors:  Raymond T Krediet; Dirk G Struijk
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

Review 5.  Icodextrin: a review of its use in peritoneal dialysis.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Molecular weight of polydisperse icodextrin effects its oncotic contribution to water transport.

Authors:  Kohei Nishimura; Yohei Kamiya; Keiichi Miyamoto; Shinsuke Nomura; Takashi Horiuchi
Journal:  J Artif Organs       Date:  2008-10-05       Impact factor: 1.731

Review 7.  The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis.

Authors:  Li Wang; Shougang Zhuang
Journal:  Perit Dial Int       Date:  2015 Sep-Oct       Impact factor: 1.756

8.  Treatment of severe ultrafiltration failure with nonglucose dialysis solutions in patients with and without peritoneal sclerosis.

Authors:  Watske Smit; Marja M Ho-Dac-Pannekeet; Raymond T Krediet
Journal:  NDT Plus       Date:  2008-10

9.  Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children.

Authors:  Graham Woodrow; Stanley L Fan; Christopher Reid; Jeannette Denning; Andrew Neil Pyrah
Journal:  BMC Nephrol       Date:  2017-11-16       Impact factor: 2.388

10.  No increase in small-solute transport in peritoneal dialysis patients treated without hypertonic glucose for fifty-four months.

Authors:  Dominique Pagniez; Alain Duhamel; Eric Boulanger; Celia Lessore de Sainte Foy; Jean-Baptiste Beuscart
Journal:  BMC Nephrol       Date:  2017-08-31       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.